Blank Bio provides pharma teams with bulk RNA‑seq‑based tools to improve clinical trial design and patient selection.
Funding
Funding not disclosed
Founders
Product
Problem
Pharmaceutical clinical trials often rely on limited biomarkers and coarse proxies of patient biology, leading to high failure rates and the need for large participant cohorts to achieve statistical power.
Solution
Blank Bio leverages bulk RNA‑seq data to provide molecularly informed tools for trial design and patient selection. Their disease trajectory modeling generates prognostic scores that predict individual disease progression, enabling trial designs that require fewer patients while maintaining statistical robustness. The patient selection platform analyzes molecular differences to identify likely responders, uncover resistance mechanisms, and suggest combination strategies, thereby improving the likelihood of therapeutic success.
Target Audience
Primary customers are pharmaceutical development teams and clinical trial designers seeking molecularly driven patient stratification and trial optimization.
Features
- Bulk RNA‑seq based disease trajectory models that produce quantitative prognostic scores for individual patients
- Covariate adjustment methods to incorporate molecular profiles into trial power calculations
- Patient selection analytics that highlight molecular signatures associated with treatment response
- Identification of emerging resistance pathways and recommendation of potential drug combinations
- Scalable platform designed to process large volumes of clinical RNA‑seq data for actionable insights